<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050513</url>
  </required_header>
  <id_info>
    <org_study_id>229BRC21.0097</org_study_id>
    <nct_id>NCT05050513</nct_id>
  </id_info>
  <brief_title>Evaluation of HEMO2Life® for Kidney Graft Preservation (OXYOP): 4 Years Follow-up</brief_title>
  <acronym>OXYOP4</acronym>
  <official_title>Evaluation of a Marine OXYgen Carrier (HEMO2Life®) for hypOthermic Kidney Graft Preservation Before Transplantation (OXYOP): 4 Years Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      4 years follow-up of the oxyop study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxyop (NCT02652520 PHRC) was a safety study evaluating the use of an oxygen carrier&#xD;
      HEMO2life® as an additive in organ preservation solution in 60 transplanted kidneys. This was&#xD;
      a national multicenter (6 centers) open-labeled safety study on HEMO2life® that included 58&#xD;
      recipients. The first patient was included on March 24th, 2016 and the study was completed on&#xD;
      February 23th, 2018 (1 year of recruitment and 1 year of follow-up). We also analyzed some&#xD;
      efficacy secondary end points using a paired analysis (local kidney receiving HEMO2life®&#xD;
      versus contralateral kidney transplanted elsewhere in France). Oxyop4 aims to analyse 4 years&#xD;
      results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>4 years</time_frame>
    <description>estimated GFR (CKDEPI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient survival</measure>
    <time_frame>4 years</time_frame>
    <description>patient survival at last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft survival</measure>
    <time_frame>4 years</time_frame>
    <description>graft survival at last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rejection rate</measure>
    <time_frame>4 years</time_frame>
    <description>biopsy proven rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection rate</measure>
    <time_frame>4 years</time_frame>
    <description>all infection episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization</measure>
    <time_frame>4 years</time_frame>
    <description>number of hospitalization, hospital stay</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Transplant; Complication, Failure</condition>
  <arm_group>
    <arm_group_label>interventional group</arm_group_label>
    <description>kidney graft preserved with M101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>kident graft preserved in standard condition (without M101)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        116 patients previously included in the oxyop study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed patients participating to the oxyop study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients refusing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick le Meur</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Brest France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yannick Le Meur, MD, PhD</last_name>
    <phone>02.98.34.70.74</phone>
    <email>yannick.lemeur@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle Ratajczak</last_name>
    <phone>02.98.34.70.61</phone>
    <email>christelle.ratajaczak@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Ratajczak</last_name>
      <phone>0298347061</phone>
      <email>christelle.ratajaczak@chu-brest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal transplantation</keyword>
  <keyword>organ preservation</keyword>
  <keyword>oxygen carrier</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning three years and ending five years following the final study report completion.</ipd_time_frame>
    <ipd_access_criteria>Data access request will be reviewed by the internal committee of Brest University Hospital. Requestor will be required to sign and complete a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

